

## NEWSLETTER

### CHEMICAL & PHARMACEUTICAL 19 - 25 January 2026



#### **Ningbo signed strategic cooperation agreement**

The Ningbo Municipal People's Government and China National Chemical Engineering Group Co., Ltd. officially signed a strategic cooperation framework agreement which will focus on deepening collaboration in cutting-edge fields such as new chemical materials and green low-carbon technologies and jointly build a more resilient and competitive modern chemical industry cluster. **(ChemNet Chemical Industry Headlines)**

#### **Ministry of Commerce Initiates Anti-dumping Investigation into Imported EPDM Rubber**

In accordance with Article 48 of the Anti-dumping Regulations of the People's Republic of China, the Ministry of Commerce has decided to conduct a sunset review investigation on the anti-dumping measures applicable to imported EPDM rubber originating in the United States, South Korea, and the European Union, effective December 20, 2025. **(ChemNet Chemical Industry Headlines)**

#### **Luxi Chemical leads joint venture to integrate polycarbonate industry resources**

Luxi Chemical Group Co., Ltd. announced that it will lead the establishment of a joint venture, with the core objective of integrating domestic polycarbonate industry resources. By strengthening industry concentration and deepening technological collaboration, it aims to precisely address the current fierce competition and continuously upgrade market demands in the polycarbonate market. **(ChemNet Chemical Industry Headlines)**

#### **Sanofi's innovative diabetes injection Tzield wins approval in China**

Sanofi has received Chinese approval for its innovative injection, Tzield. The medication is designed to delay the progression of type 1 diabetes by protecting pancreatic function, offering patients nearly three extra years before insulin dependence begins. China is home to about 600,000 type 1 diabetes patients, ranking third globally in cases. The rapid approval reflects China's push to accelerate access to new treatments. **(China Daily)**

#### **Daiichi Sankyo sets up new unit in Shanghai**

Daiichi Sankyo is investing 1.1 billion yuan (120 million euro) to build a new ADC (Antibody-Drug Conjugate) production facility in Shanghai. As a national pilot program, this project will localize manufacturing and adopt a cross-border segmented production model. The move reflects the company's long-term commitment to the China market, aiming to deliver advanced cancer therapies more efficiently. **(China Daily)**